Rising Viral Infections Driving Market Growth: The Driving Engine Behind Common Warts Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Common Warts Market Size Growth Forecast: What to Expect by 2025?
The overall size of the market dealing with common warts has seen robust expansion lately. Projected figures indicate a rise from a valuation of $2.13 billion in 2024 to $2.25 billion by 2025, reflecting a consistent annual increase rate (CAGR) of 5.9%. Several factors underpin this expansion observed during the historical timeframe, including heightened public knowledge concerning dermatological wellness, a greater frequency of wart occurrences, intensifying consumer desire for procedures that do not involve incisions, broader application of cryotherapy techniques, and the proliferation of specialized dermatology centers.

How Will the Common Warts Market Size Evolve and Grow by 2029?
Anticipation is high for substantial expansion within the common warts market, projecting its valuation to reach $2.81 billion by 2029, fueled by a consistent compound annual growth rate (CAGR) of 5.7%; this upward trajectory in the coming years is anticipated largely due to several key factors, including an increasing number of elderly individuals, the escalating incidence of viral infections, greater uptake of sophisticated dermatological procedures, a rising need for tailor-made care, and consumers increasingly favoring treatment administered at home.

View the full report here:
https://www.thebusinessresearchcompany.com/report/common-warts-global-market-report

What Drivers Are Propelling the Growth of Common Warts Market Forward?
A rising frequency of viral illnesses is anticipated to fuel the expansion of the market for treating common warts in the future.These ailments stem from viruses invading, replicating, and disseminating throughout the body, thereby impacting cellular processes and the body's defense mechanisms.Factors such as increased global connectivity, shifts in climate patterns, the growth of cities, the clearing of forests, and diminished immunity contribute to the growing rate of these viral infections.Therapies for common warts specifically address the human papillomavirus (HPV) that causes these growths, offering crucial assistance to those afflicted by viral infections by curbing the virus's transmission, easing associated pain, and facilitating recovery, which in turn helps avert subsequent issues like secondary infections or scarring and enhances the overall well-being of the patient.To illustrate this trend, data from the Centers for Disease Control and Prevention, an American governmental body, showed that in 2022, the percentage of varicella cases verified via PCR jumped by 62 percent, moving from 29 percent to 47 percent within the preceding five years, as reported in 2024.Moreover, in January 2023, the National Foundation for Infectious Diseases, a US health organization, estimated that approximately 14 million new cases of HPV infection emerge in the United States each year.Consequently, the escalating prevalence of viral diseases serves as a key catalyst for the growth observed in the common warts treatment sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21154&type=smp

Which Emerging Trends Are Transforming the Common Warts Market in 2025?
Key players within the common warts marketplace are currently prioritizing the development of cutting-edge solutions, specifically dermatological interventions, in response to the escalating need for remedies that are both efficacious and readily available, with the ultimate goal of enhancing recovery rates for patients and widening their footprint across the dermatology industry. Since dermatological therapies encompass medical approaches designed to address various skin ailments such as infections, inflammatory responses, and other irregularities, an illustrative event occurred in May 2024 when Verrica Pharmaceuticals, a firm situated in the United States, established a licensing pact with Torii Pharmaceutical Co. Ltd., a counterpart based in Japan; this joint venture's objective is to finance a worldwide Phase 3 clinical investigation concerning YCANTH, a therapeutic agent specifically targeting common warts, thereby bolstering YCANTH's progression into later development stages and increasing its worldwide availability, with Torii Pharmaceuticals providing the requisite capital infusion for this advancement, ultimately fortifying the dermatology offerings and worldwide standing of both organizations.

What Are the Key Segments in the Common Warts Market?
The common wartsmarket covered in this report is segmented -

1) By Treatment Method: Cryotherapy; Laser Treatment; Electrosurgery; Topical Medications
2) By Patient Demographics: Children; Adults; Elderly
3) By Disease Stage: Initial Stage; Moderate Stage; Severe Stage
4) By End User: Hospitals; Dermatology Clinics; Home Care

Subsegments:
1) By Cryotherapy: Liquid Nitrogen Therapy; Carbon Dioxide Therapy
2) By Laser Treatment: Pulsed-Dye Laser Therapy; Carbon Dioxide (CO2) Laser Therapy
3) By Electrosurgery: Curettage And Electrosurgical Removal; High-Frequency Electrosurgical Ablation
4) By Topical Medications: Salicylic Acid-Based Therapy; Immunotherapy-Based Topicals; Retinoid-Based Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21154&type=smp

Who Are the Key Players Shaping the Common Warts Market's Competitive Landscape?
Major companies operating in the common warts market are Major players in the market are AbbVie Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Limited, Perrigo Company plc, Holland & Barrett International Limited, Prestige Consumer Healthcare Inc., Maruho Co. Ltd., Novan Inc., X4 Pharmaceuticals Inc., Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., RXi Pharmaceuticals Corporation, Scholl's Wellness Company, Nielsen BioSciences Inc., Cassiopea S.p.A., Orgenesis Inc., KinoPharma Inc., Naturasil, Veradermics Inc., KinoPharma Co. Ltd.

What Geographic Markets Are Powering Growth in the Common Warts Market?
North America was the largest region in the common warts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the common warts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21154

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.